Delivery Order SPE2DB22D2206-SPE2DB26FDU89
- Not listed
- The Defense Logistics Agency awarded a $3,285.27 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Phenobarbital 130 mg/ml vials. The contract represents a non-set-aside competitive award with an ultimate completion date of August 29, 2025, and performance location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency awarded a $5,149.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp on May 21, 2025, for the supply of Phenobarbital 130 mg/mL vials. This is a non-set-aside contract with an ultimate completion date of May 22, 2025, to be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single-line item pharmaceutical procurement supporting federal medical supply needs. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $3,650.78 to AmerisourceBergen Drug Corp for the supply of Phenobarbital 130 mg/mL vials, with a completion date of June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, serves as...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Phenobarbital 65 mg/mL vials. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,018.74 and is scheduled for completion by August 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this requirement from its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Phenobarbital 65 mg/mL vials with a firm fixed price ceiling value of $1,552.57. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 25, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this requirement from its corporate office location. This delivery order is issued under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a $6,483.54 delivery order to AmerisourceBergen Drug Corp for Phenobarbital 130 mg/ml vial on September 23, 2025, with completion scheduled for September 24, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Phenobarbital 130 mg/mL vials valued at $3,749.73 on September 29, 2025. This firm fixed-price, competitively awarded delivery order is non-set-aside and scheduled for completion by September 30, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a continuation of the company's substantial pharmaceutical supply relationship with the federal...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Phenobarbital 65 mg/ml vials, with a ceiling value of $4,516.61 and an ultimate completion date of September 8, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on June 9, 2025, for the supply of Phenobarbital 65 mg/mL vials with a ceiling value of $1,442.24. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of June 10, 2025. The contract is funded by the Defense Logistics Agency's Medical Supply Chain division, which procures critical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $1,089.00 for Phenobarbital 65 mg/mL vials by the Defense Department's Medical Supply Chain. This contract, awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed price contracting and was awarded competitively with no set-aside designation. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB26FDU89Delivery Order
The Defense Logistics Agency awarded a $7,103.27 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Phenobarbital 130 mg/ml in vial format. The contract was competitively awarded without set-aside designation and is scheduled for completion by October 30, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. This prime pharmaceutical supply vehicle enables the contractor to deliver a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. The IDC represents a strategic sourcing mechanism through which the agency fulfills ongoing pharmaceutical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 10/29/25 |